Save the date for

Sustainable Strategies for Generics & Biosimilars

06th March - 07th March 2017

More about the Venue


Key topics

  • Generic business development & risk reduction
  • Sustainable product portfolio for generics & biosimilars
  • Supergenerics vs generics
  • Cost containment and procurement of generics & biosimilars
  • Redesign & optimization of generics & biosimilar model
  • Regulatory differences in the EU, US & regions of interest
  • Creating new market segments
  • Generics in 2020 and beyond

Why to attend

  • Challenges of drug low prices and low margins
  • Health policy implications and recent evolutions
  • Approval pathways and registration issues
  • Expanding role of the OTC market as an INN defense
  • Porters five forces analysis
  • Tailoring new business models via licensing
  • New therapeutic uses & repositioning
  • Latest IP and regulatory changes
  • Sustainable product portfolios for Generics & Biosimilars
  • Entry keys into the new markets
  • Insight to patent litigation and compulsory licensing
  • The innovator response to Biosimilars

Want to know more?

Learn the full details about the event program in the downloadable agenda.

Who should attend


Product portfolio managers, Business developers, Strategic planners

Heads of R&D, Regulatory affairs, Market access

M&A, Intellectual property, Pricing & reimbursement


  • Pharmaceutical
  • Generics
  • Biosimilars
  • Healthcare